Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis

Clinical Trial ID NCT01932554

Rank	Title	Journal	Year	PubWeight™‹?›
1	Mortality in sickle cell disease. Life expectancy and risk factors for early death.	N Engl J Med	1994	15.82
2	Pain in sickle cell disease. Rates and risk factors.	N Engl J Med	1991	9.75
3	Pathogenesis and treatment of sickle cell disease.	N Engl J Med	1997	4.04
4	Management of sickle cell disease.	N Engl J Med	1999	2.73
5	Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor.	Blood	2000	1.77
6	Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (first of three parts).	N Engl J Med	1978	1.72
7	Hypercoagulability in sickle cell disease: new approaches to an old problem.	Hematology Am Soc Hematol Educ Program	2007	1.65
8	Hypercoagulability in sickle cell disease: a curious paradox.	Am J Med	2003	1.47
9	Guidelines for the management of the acute painful crisis in sickle cell disease.	Br J Haematol	2003	1.41
10	Perspectives series: cell adhesion in vascular biology. Adhesive interactions of sickle erythrocytes with endothelium.	J Clin Invest	1997	1.08
11	Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (second of three parts).	N Engl J Med	1978	1.08
12	Sickle cell disease.	Pediatr Clin North Am	1996	0.91
13	Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.	Blood	2016	0.87
14	Small-molecule cyclic alpha V beta 3 antagonists inhibit sickle red cell adhesion to vascular endothelium and vasoocclusion.	Am J Physiol Heart Circ Physiol	2007	0.81